Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

In the phase 3 EPCORE DLBCL-1 study comparing single-agent epcoritamab against chemoimmunotherapy, epcoritamab demonstrated markedly superior 36-month progression-free survival (27% versus 8%), but failed to show a statistically significant overall survival benefit for US regulatory endpoints. Dr. Elizabeth Budde noted this discrepancy was driven by trial execution during the COVID-19 pandemic, where a 37% COVID-19 infection rate and 17% mortality in the epcoritamab cohort compromised overall survival findings.

Related Insights

The 5-year follow-up of the Polarix trial revealed an unexpected overall survival benefit for patients with the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma. This post-hoc finding suggests the drug's efficacy is not uniform and is most pronounced in this historically harder-to-treat patient group, challenging initial interpretations of the data.

The confirmatory Code Break 200 study for sotorasib demonstrated a statistically significant improvement in progression-free survival (PFS) over docetaxel. However, it failed to show a similar benefit in overall survival (OS), a critical distinction for oncologists weighing long-term patient outcomes.

Higher death rates observed in the triplet therapy arms of recent CLL trials (e.g., AMPLIFY) were significantly impacted by the COVID-19 pandemic, as anti-CD20 antibodies increase infection risk. This historical context complicates the interpretation and generalizability of the toxicity data in a post-pandemic era.

Long-term follow-up from the Epcor-NHL1 trial reveals that epcoritamab monotherapy can produce highly durable complete responses in relapsed/refractory large B-cell lymphoma. With some patients remaining in remission for over 54 months, the therapy is positioned as a potential curative option in this setting.

The Durvalumab monotherapy arm showed a promising disease-free survival signal (HR 0.74), but due to reduced recruitment from COVID-19, the trial was underpowered for statistical significance. This shows how external factors can compromise a trial's ability to deliver a definitive clinical answer, leaving a potentially effective therapy in limbo.

The belief that immune-related adverse events (irAEs) predict better response to immunotherapy is likely confounded by survival bias. Patients must remain on treatment long enough to both respond and develop an irAE. This extended duration creates a correlation that may not be causal.

In the AMPLIFY trial, the acalabrutinib-venetoclax (AV) arm showed superior overall survival. This was heavily influenced by the COVID-19 pandemic, as regimens containing the anti-CD20 antibody obinutuzumab (AVO and chemo) had significantly more fatal COVID cases, making the antibody a liability during that period.

In solid tumor immunotherapy, significant efficacy gains almost always correlate with increased toxicity. This study's claim of nearly doubled progression-free survival with identical toxicity rates is biologically implausible and was a primary reason for skepticism, even before analyzing the trial's methodology.

During the pandemic, a multicenter mezigdomide trial had zero COVID-19 deaths. This contrasts sharply with bispecific antibody trials in similar populations, which reported significant COVID mortality. This suggests CELMoDs have a more favorable immune profile for managing viral infections in immunocompromised patients.

Long-term follow-up from the pivotal epcoritamab trial reveals that 46% of DLBCL patients who achieve a complete remission maintain it at four years. This durability provides strong evidence that bispecific monotherapy, not just CAR-T, can be a curative treatment for a subset of patients.

Pandemic COVID-19 Mortality Confounded Overall Survival Benefits in Epcoritamab's Phase 3 DLBCL Trial | RiffOn